Sia Daneshmand, MD, presented “Updates in Muscle Invasive Bladder Cancer” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Daneshmand, Sia. “Updates in Screening: Prostate Cancer Guidelines.” August 10th, 2020. Accessed Nov 2024. https://grandroundsinurology.com/updates-in-muscle-invasive-bladder-cancer/
Summary:
Sia Daneshmand, MD, Associate Professor of Urology and Director of Clinical Research at the University of Southern California, describes the current landscape of muscle invasive bladder cancer treatment, highlighting developments in radical cystectomy and chemotherapy. He observes that while radical cystectomy has long been the gold standard, efforts are being made to preserve reproductive organs in female patients who have low-stage disease. Dr. Daneshmand also notes the significant number of neoadjuvant chemotherapy phase II trials currently underway. While studies examining adjuvant chemotherapy have shown promise, the limitations of these trials necessitate further research. Similarly, research comparing super-extended lymph node dissection (LND) with extended LND have yielded insignificant p-values, but absolute numbers demonstrate a positive upward survival trend over 5 years. Dr. Daneshmand concludes that additional clinical trials will reveal the optimal combination and sequencing of treatment options.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Daneshmand presented this lecture during this year’s virtual conference in August 2020.
ABOUT THE AUTHOR
Siamak Daneshmand, MD, is Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as Director of Urologic Oncology, as well as the Urologic Oncology (SUO) Fellowship Director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve perioperative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer, as well as the AUA guidelines panel for testicular cancer. He currently serves as the chair of bladder section of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials, and has led over a dozen clinical trials in bladder cancer and a pivotal trial in testicular cancer (SEMS). He is currently secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 12 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG Cancer Research Network local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored over 375 peer-reviewed articles, reviews, and book chapters.
Dr. Daneshmand earned his medical degree at the University of California, Davis, and completed his residency at the University of Southern California, followed by a two-year fellowship in Urologic Oncology at the University of Southern California’s Norris Comprehensive Cancer Center.